drugset / Trial / NCT05027672
Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.
RandomizedParallel-groupSingle-blindHealth-services research
Summary
To determine whether a heterologous vaccination regimen in individuals with no known previous history of COVID-19 is non-inferior to that observed with counterpart regimens currently in use in Argentina among persons aged 21 to 65 years
Timeline
- Start
- 2021-07-30
- Primary completion
- 2021-08-30
- Completion
- 2021-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD1222 | Vaccine | — | — |
| Subject | Elasomeran | Messenger RNA (mRNA) | — | — |
| Subject | Gam-COVID-Vac (rAd26) | Vaccine | — | — |
| Subject | Gam-COVID-Vac (rAd5) | Vaccine | — | — |
Indications
No indication recorded.